- Boosting
the early detection of the second most common cancer in the country&nbsp; Recently, BGI Genomics' COLOTECT™&nbsp;1.0 DNA Methylation Detection Kit for Human SDC2, ADHFE1, and PPP2R5C Genes
(Real-Time PCR), Sample Pretreatment Kit for Methylation Detection, DNA
Isolation Kit, Stool Sample Collection Kit have received market authorization
from Malaysia's Medical Device Authority (hereinafter referred to as MDA).With this
certification, COLOTECT™
1.0 is now available
in over six countries/regions and markets that recognize these certificates. COLOTECT™
1.0 is eligible for EU market entry, and has obtained MDMA in Saudi Arabia,
MHRA registration in the UK, TFDA certification in Thailand, ANVISA certification
in Brazil, Certificate of Listing in Hong Kong, and ARTG certificate in
Australia. This flagship oncology product will help accelerate the company's
international business growth.



COLOTECT™
1.0 is a non-invasive, highly sensitive test for colorectal cancer (CRC) and
precancerous lesions. Users could do this test from home to provide fecal
samples for multi-methylation-specific PCR to detect abnormal CRC gene markers.
Detecting the methylation status of exfoliated cell genes in the intestine
helps detect colorectal cancer and precancerous lesions risk and colorectal
cancer risk, even without active bleeding lesions.<img src="https://cdn.it.bgi.com/source/colotectnologoresized.png" style="max-width:100%;" contenteditable="false"/>Colorectal
cancer is the third most common cancer and the second deadliest cancer
globally. It is estimated that. In 2020, colorectal cancer diagnoses worldwide
were about 1.9 million. Older age, a history of bowel disease, a family history
of related conditions, having type 2 diabetes, being overweight or obese,
certain types of diet, smoking, and drinking are all risk factors that can lead
to colorectal cancer. The incidence rate of colorectal cancer among young
people has also increased significantly in recent years.However,
colorectal cancer usually does not show any symptoms in the early stages, which
causes nearly 50% of patients not to be detected until they reach the third or
fourth stage and miss the best time for treatment. If colorectal cancer is
diagnosed at an early stage, the 5-year relative survival rate of patients can
be as high as 90%. Conversely, if it is stage IV at the time of discovery, the
5-year survival rate will be reduced to only about 10%.According
to the National Colorectal Cancer Screening Programme (Opportunistic) in
Malaysia. From 2014 to 2018, 127,957 people in Malaysia screened for immunological
Fecal Occult Blood Tests or iFOBT, of whom 9.3% were positive for iFOBT and
recommended colorectal surgery. 6,548 people in Malaysia eventually underwent a
colonoscopy, 13.9% were found to have polyps in the colon, with only 266 (4.1%)
were diagnosed with colorectal cancer.iFOBT
screening problems include the lack of awareness regarding CRC screening, the
embarrassment of collecting stool samples, and people who got positive but
missed the diagnosis. There are also issues related to poor access to
colonoscopy and the lack of monitoring as well as follow-up. <img src="https://cdn.it.bgi.com/source/colotect2.png" style="max-width:100%;" contenteditable="false"/>COLOTECT™
1.0's product advantages are:<ul><li>Convenient
– Self-sampling at home. No special prep or need for time off.</li><li>Effective
– Highly sensitive. 87% CRC and 42.1% advanced adenoma accuracy.</li><li>Precise
- Specificity is as high as 93%.</li><li>Total
solution – Provide a complete set of sampling, processing, and testing kits.</li><li>Simple
workflow - Only a
small, one-time sample is needed.</li><li>High
quality - Stringent Quality Control Measures; ISO 13485 certified manufacturer.</li></ul>















Over the
years, BGI Genomics has invested in research and clinical transformation in oncology.
In the future, the company will expand its research in this domain, launch more
customized services, and develop related testing reagents to contribute to
precision medicine and safeguard public health.&nbsp;Additional Reading:<a target="_blank" href="https://www.bgi.com/global/news/bgi-genomics-2023-global-state-of-colorectal-cancer-awareness-report">BGI Genomics 2023 Global State of Colorectal Cancer Awareness Report</a><a href="https://www.bgi.com/global/news/dna-methylation-tests-facilitate-earlier-colorectal-cancer-treatment-bgi-perspectives">DNA methylation tests enable better colorectal cancer treatment - BGI Perspectives</a>&nbsp;<a target="_blank" href="https://www.bgi.com/global/news/nationwide-early-screening-is-key-to-fighting-cancer-treatment-global-inequalities-bgi-perspectives">Early cancer screening helps fight global cancer treatment inequalities - BGI Perspectives</a><a target="_blank" href="https://www.bgi.com/global/news/7-questions-about-colorectal-cancer-non-invasive-fecal-dna-testing-bgi-perspectives">7 Questions about Colorectal Cancer &amp; Non-invasive Fecal DNA Testing l BGI Perspectives</a>About BGI Genomics <a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

COLOTECT™ 1.0 awarded MDA Certificate in Malaysia

<img src="https://cdn.it.bgi.com/source/230601-1.jpg" contenteditable="false" style="color: rgba(0, 0, 0, 0.85); font-size: 14px; max-width: 100%;"/> BGI&nbsp;Genomics, a leading provider of multi-omics solutions, will be attending the 56th European Society of Human Genetics (ESHG) Conference from June 10–12, 2023, in Glasgow, Scotland, UK.If you are attending, please stop by at booth 724 to speak with us about our latest innovations and solutions in multi-omics. We would love to discuss how we can support your upcoming projects.BGI&nbsp;Genomics&nbsp;offers multi-omics services to look across genomics, transcriptomics, epigenomics, proteomics, and metabolomics, with the flexibility to customize solutions that meet your specific needs. All projects are supported by a bioinformatics infrastructure.Corporate Satellite Session We are hosting a corporate
satellite session during the ESHG Conference on “Leveraging multi-omics
solutions to accelerate life sciences innovation”. We are excited about the
speakers and presentations and look forward to seeing you at our
workshop!&nbsp;Date: Sunday, June 11thTime: 18:30 – 20:00 BSTLocation: Carron, first floor, SEC, Exhibition WaySession number:
CS28&nbsp;&nbsp;&nbsp;&nbsp;Refreshments and hot drinks will be served while supplies last. Also, don’t forget to stop by our booth #724 to receive our special offers and gifts.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;








<img src="https://cdn.it.bgi.com/source/230606-CS Event.jpg" style="max-width:100%;" contenteditable="false"/>In addition, we look forward to meeting you at ESHG where we're offering:<img src="https://cdn.it.bgi.com/source/230606-1.png" style="max-width:100%;" contenteditable="false" width="100%"/>Exclusively for ESHG Attendees!Dr. Tom System&nbsp;Mine your RNA-Seq
Data on&nbsp;Dr. Tom&nbsp;for Free!<a href="https://www.bgi.com/global/service/dr-tom?utm_campaign=2023%20ESHG&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-_hY7elU9Xdt2TGSLvm0G8s7Cn_40iqQrcHiNrZgBHUaFOxKIwsqdKumqxl_2o4N3ml0QkG" target="https://7024340.hubspotpreview-na1.com/_hcms/preview/email/_blank">Dr. Tom's</a>&nbsp;multi-omics
data mining system is a web-based solution for the convenient analysis,
visualization, and interpretation of RNA data, including mRNA, lncRNA and
miRNA.Highlights:<ul>
 <li>If you
 already have read count after alignment and quantification, upload the
 read count and analysis for free.</li>
 <li>Complete
 results of gene quantification, gene annotation, DEGs detection, gene
 enrichment and other advanced analysis.</li>
 <li>Abundant
 interactive tools such as network and heat-map for multi-omics data
 visualization.</li>
 <li>Integrated
 information from public databases.</li>
</ul><ul><li>





Delicate plots with
customized adjustments of color, size, and text.</li></ul>* Terms and conditions apply.Multi-omics Free for Correlation Analysis!BGI Genomics offers multi-omics services to
look across genomics, transcriptomics, epigenomics, proteomics and
metabolomics, with the flexibility to customize solutions that meet your
specific needs. All projects are supported by a bioinformatics infrastructure.Highlights:



<ul><li>Proteome
 + Transcriptome</li><li>Metabolome
 + Metagenomic Survey</li><li>Metabolome
 + Proteome</li><li>Quantitative
 Proteome + Phosphoproteome</li><li>Free
 correlation analysis for all multi-omics services</li></ul>* Terms and conditions apply.High-throughput Targeted Metabolomics DetectionHM Pro2300 35% off!<div>BGI Genomics provides one of the world's most comprehensive panels
for targeted metabolomics research. HM Pro2300 can simultaneously detect more
than 2,000 metabolites, including 700 small molecules and more than 1600 lipids
which covers all kinds of important metabolites and core metabolic pathways.

Highlights:

<ul>
 <li>Targeted
 detection of 700 small molecules and more than 1600 lipids.</li>
 <li>Through
 derivatization, the sensitivity of detection increases up to 300 times.</li>
 <li>Metabolomics
 quantification by using standard curves and internal standards, with
 excellent accuracy and precision.</li>
 <li>With
 automated workstations, the daily sample preparation throughput can reach
 over 1000. 
 Multi-omics data analysis on interactive bioinformatics platform Dr. Tom.</li><li>The analysis software automatically performs data preprocessing and metabolite quantitative analysis.&nbsp;</li>
</ul>

 Promotion Disclaimer:&nbsp;

- Other RNA transcriptome sequencing
promotional offerings available

- For Multi-Omics and HM Pro2300 services,
this promotion is valid for contract signed before&nbsp;June 30,
2023&nbsp;and sample submitted before&nbsp;July 31, 2023- This promotion cannot be combined with other BGI Genomics promotions</div>

Join us at the ESHG Conference 2023 in Glasgow

- Over 2,800
cases, representing a 31 percent increase, added to BGI Genomics-led
CardioGen's Hereditary Cardiovascular Disease Gene Data<img src="https://cdn.it.bgi.com/source/cardiogen.png" style="max-width:100%;" contenteditable="false"/>BGI
Genomics, together with the National Center for Cardiovascular Diseases, Fuwai
Hospital, and the State Key Laboratory of Cardiovascular Diseases, is pleased
to announce an upgrade of the CardioGen automated interpretation system, the
"Genotype and Phenotype Database of Monogenic Cardiovascular
Disease." This upgrade covers the addition of over 2,800 cases from the
initial 9,000 cases, covering monogenic hereditary hypertension, cardiac ion
channel disease, and pulmonary arterial hypertension.The
cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy, and
arrhythmogenic cardiomyopathy) component of CardioGen was earlier included in a
trial release in January 2023.



<a href="https://cardiogene.bgi.com/#/home">CardioGen</a>&nbsp;comprehensively collects and integrates information
on the variant loci of disease-causing genes reported in the global literature
and public databases, as well as clinical phenotypes of patients, to facilitate
accurate interpretation of the variant loci by clinicians once the genetic test
results are available. As this database grows, clinicians will be able to make
more accurate clinical interpretations after receiving genetic test results.<img src="https://cdn.it.bgi.com/source/cardiogenhomepage.png" style="max-width:100%;" contenteditable="false"/>System
Highlights1: Visual
displayThe database
is published on a website, providing a search function for genes and gene
locus, providing a visual display of such information with
the&nbsp;addition&nbsp;of phenotype.2: More
convenient clinical application and analysis







Compared
with other databases, CardioGen also includes the clinical phenotypes of
patients with monogenic cardiovascular diseases carrying pathogenic variants
and provides more clinical reference information for genetic diagnosis.<img src="https://cdn.it.bgi.com/source/cardiogensearchpage.png" style="max-width:100%;" contenteditable="false"/>3: More abundant
data sourcesBesides the
genetic information and clinical phenotypes of monogenic cardiovascular
diseases reported in English literature, CardioGen also offers publicly
available information and research data found in Chinese literature.&nbsp;This
enhances the reliability of genetic testing data for patients worldwide.4: More
accurate site interpretationBased on the
standardized variant interpretation guidelines jointly published by the
American College of Medical Genetics &amp; Genomics (ACMG) and the Association
for Molecular Pathology (AMP) in 2015, the team of experts customized
site-specific interpretation rules for monogenic cardiovascular diseases, used
information collected in the database of genetic variants and aggregated
clinical information. CardioGen automated the interpretation process,&nbsp;presenting
accurate results suitable for clinical use.In addition,
as genotype-phenotype association information gets constantly updated,&nbsp;the
system will automatically update the loci interpretation results to further
enhance accuracy.Upgraded and
optimized content1: Expansion
of disease categoriesBased on the
database of cardiomyopathies, three new categories of monogenic hereditary
cardiovascular diseases have been added:<ul><li>Monogenic
hereditary hypertension: including Liddle syndrome, Gordon syndrome, episodic
salpingitis, etc.;</li><li>Cardiac ion
channel disease: including long QT syndrome, short QT syndrome, Brugada
syndrome, etc.;</li><li>Pulmonary
arterial hypertension. Through keyword-based literature searches and manual
phenotype extraction, the upgraded database has more comprehensive coverage of
disease categories and richer genotypic associations.</li></ul>2: More
cases and more complete phenotype























Based on the
new diseases and keywords gathered from associated genes, the researchers
conducted a literature search in the Chinese and English databases, read,
filtered, and extracted the associations between genetic loci and phenotypes. This
update adds more than 2,800 cases from the literature and customizes different
case phenotype display pages for different diseases&nbsp;so that the
association between genetic information and phenotype information is more
accurate.3: Database
expansion and update

Along with
the increase in disease types, the number of&nbsp;associated pathogenic
genes has increased from 21 to 59,&nbsp;and the&nbsp;number of included
Clinvar loci has increased from nearly 50,000 to nearly 90,000, with richer
searchable contents. The annotated database focuses on the content of the
Clinvar database, and this update also upgrades the version of the Clinvar
database to 20230318, with more accurate pathogenicity information.We welcome
clinicians to test-drive the&nbsp;<a href="https://cardiogene.bgi.com/#/home" target="_blank" style="font-size: 16px; letter-spacing: 0px; text-align: center; background-color: rgb(255, 255, 255);">CardioGen website</a>.About BGI
Genomics



<a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen, China, is the
world's leading integrated solutions provider of precision medicine. Our
services cover over 100 countries and regions, involving more than 2,300
medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics
(300676.SZ) was officially listed on the Shenzhen Stock Exchange.

CardioGen Upgrade Helps Clinicians Accurately Diagnose Monogenic Cardiovascular Diseases

- BGI Genomics Extends Presence Across Argentina, Brazil, and Chile to Enhance Health Outcomes<img src="https://cdn.it.bgi.com/source/boh.jpg" style="max-width:100%;" contenteditable="false"/> BGI Genomics and Brazlex
Medical Genetics signing an agreement in Sao PauloBGI Genomics recently participated in a business mission to South America in April 2023. Given that this continent ranks fourth in area and fifth in population worldwide, the economic and healthcare enhancement potential of this continent is compelling. Every South
American country faces different healthcare challenges and priorities. Still,
the promise of precision medicine is clear: It offers an opportunity to shift
the delivery of care from a legacy one-size-fits-all approach to applying the
right treatment for the right patient at the right time.



To help
deliver on precision medicine's potential, BGI Genomics considers genetic
testing to be pivotal to the medical screening, diagnosis and treatment of
diseases. As a leading integrated solutions provider of precision medicine, the
company looks forward to long-term cooperation with leading local partners to
further enhance health outcomes.At the
China-Brazil Economic and Trade Cooperation Conference in the city of Sao
Paulo, BGI Genomics and&nbsp;<a href="https://www.brazlex.com/?lang=en" target="_blank">Brazlex Medical Genetics</a>, a leader in medical testing in
the country, signed a cooperation agreement on April 17, agreeing to long-term
cooperation in clinical medical testing and introducing the company's products
and services to the Brazilian market, such as prenatal screening and cancer
tumor screening.Subsequently,
on April 17, the company signed a substantial order with&nbsp;<a href="https://www.biogenar.com.ar/" target="_blank">Biogenar</a>, a
leading precision medicine service provider in Argentina, which plans to
purchase large-scale high-throughput sequencing platform systems and related
automation equipment for local scientific research and enhance clinical
services.On April 17, BGI
Genomics has also reached a cooperation agreement with diagnostic service
carrier&nbsp;<a href="https://biocodices.com/" target="_blank">Biocodices</a> will
provide a complete set of non-invasive prenatal genetic testing equipment and
solutions to this Buenos Aires-based company. With this partnership, testing is
done locally instead of sending samples to overseas laboratories, thus reducing
the cost for local pregnant women and helping Argentina improve maternal health
services.











The
Precision Oncology Center of <a href="https://www.diariomayor.cl/">Universidad Mayor</a>, a
leading Chilean university, obtained cutting-edge sequencers and other
equipment from BGI Genomics. This partnership will help launch Chile's most
extensive cancer genomics laboratory. The signing ceremony of this agreement
was held on April 18, attended by the Vice Chancellor of Research, Nicole
Trefault, and the general manager for Latin America, BGI Genomics, Liang Wu.<img src="https://cdn.it.bgi.com/source/hugosigning.jpg" style="max-width:100%;" contenteditable="false"/> Universidad Mayor Vice
Chancellor of Research Nichole Trefault and BGI Genomics LATAM GM Liang WuDr. Patricio Manque,
Scientific Director of the Center, highlights that this is an important milestone. "The Precision Oncology Center puts medicine at
the service of the people in an unprecedented effort to move towards
democratizing access to frontier medical treatments in the area of cancer, the
leading cause of death in our country. We now can rely on the most extensive sequencing laboratory in Chile with equipment that allows analysis to be
carried out in greater depth, in less time, and at a lower cost."Liang Wu
notes that the company seeks to benefit the local population by elevating
technological health standards, "Over the past few years, we have embarked on
a series of collaborative projects in Latin America, yielding remarkable
outcomes. Our collaborations encompass establishing laboratories, providing
technical support, and implementing training programs."About BGI Genomics









<a href="https://www.bgi.com/global">BGI Genomics</a>, headquartered in Shenzhen, China, is the world's leading integrated
solutions provider of precision medicine. Our services cover over 100 countries
and regions, involving more than 2,300 medical institutions. In July 2017, as a
subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the
Shenzhen Stock Exchange.

Empowering Precision Medicine in Argentina, Brazil and Chile - BGI Updates

<img src="https://cdn.it.bgi.com/source/inglese.jpg" style="max-width:100%;" contenteditable="false" width="50%"/><img src="https://cdn.it.bgi.com/source/momsdayspanishresized.jpg" style="max-width:100%;" contenteditable="false" width="50%"/>Mother's Day is a
special occasion to honor and appreciate the mothers in our lives. At BGI
Genomics, we value the contributions and achievements of mothers and women who seek
personal happiness while balancing their work and family responsibilities. 



We feature two colleagues
who share their perspectives on motherhood and career, Natalia Pereiras, the
mother of a two-year-old girl and Laboratory Director based
in Montevideo, Uruguay, and Fang Zhang, an expecting mother who works as a
Commercial Senior Manager at BGI Genomics, based in Boston, U.S.<img src="https://cdn.it.bgi.com/source/nathalia.png" style="max-width:100%;" contenteditable="false"/>Q: What does Mother's Day mean to you?Natalia:
Mother's Day is a day to recognize the daily work of raising and accompanying
mothers during their upbringing. The important thing is to enjoy and celebrate
it with the family.&nbsp;To
adapt to the faster pace of modern life, we must balance work and family.
Family support is crucial as nobody can be everywhere all the time. With this
support, you can easily complete and enjoy your daily tasks. Though I wake up
early in the morning to bring my daughter to school, this habit fills me with
joy as it gives me a chance to spend time with her and fills me with vitality
for my workday.&nbsp;&nbsp;Fang
Zhang: Mother's Day is a time to celebrate the joys and challenges of being a
mother and express gratitude to my mother and mother-in-law for their love and
support. It is also a time to reflect on the journey of motherhood that I am
about to embark on and to prepare myself mentally and emotionally for this new
role.Q: How do you balance your work and family
commitments?&nbsp;Natalia:
I am fortunate to be able to do a job that I enjoy, and that is why I have
achieved a good balance. I hope my daughter can also accomplish this. Without
happy parents, there can be no happy children, so striving to do what we enjoy
is vital.When
we enjoy our work, we can better handle the challenges of any job! We are in
the challenging stage of launching a laboratory in Uruguay with our team, so
there are many urgent tasks, such as obtaining certification from the Ministry
of Health and other relevant departments.&nbsp;Fang
Zhang: Personally, since this is my first baby, I cherish it very much.
Especially whenever I feel fetal movement, it is my happiest moment.&nbsp;In
the U.S., family doctors have a more significant role, particularly in the
early stages of pregnancy. In addition, non-invasive prenatal testing (NIPT)
and carrier screening tests occur from week 12 of pregnancy. In China, NIPT can
be conducted from week 10 of pregnancy.&nbsp;There is nervousness and stress that comes with
motherhood, so I am grateful that my bosses have been very supportive and
flexible. I now travel shorter distances and less frequently. I also plan and
prioritize my tasks in advance to manage my time and energy more
efficiently.&nbsp;&nbsp;<img src="https://cdn.it.bgi.com/source/fangmothersday.png" style="max-width:100%;" contenteditable="false"/>Q: In what ways can companies support
or celebrate mothers and women in general? Natalia: BGI Genomics is a company that encourages a good working
atmosphere and is characterized by empathy, which is helpful to work
relationships and having time for family. Fang Zhang: We have an inclusive and caring culture. HR
colleagues proactively inquired about my well-being and informed me about
maternal leave benefits and how to apply. More importantly, the company offers working mothers equal
opportunities and career advancement. This is vital as many working mothers are
keen to continue growing at work to take on more responsibilities. Get in touch! We would love to hear from you as well. How do you think
working mothers and women, in general, can be better supported at work? Please
share your feedback or comments below @BGI Genomics on social media channels.
Happy Mother's Day to all the mothers and mother figures out there!About BGI Genomics













































<a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen China, is the world's
leading integrated solutions provider of precision medicine. Our services cover
over 100 countries and regions, involving more than 2,300 medical institutions.
In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was
officially listed on the Shenzhen Stock Exchange.

A Mother's Day Message from Uruguay and the U.S: Happy Parents Make for Happy Children

Thalassemia
(thal-uh-SEE-me-uh) is an inherited blood disorder that affects about 300
million people worldwide. Treatments for moderate to severe
thalassemia include frequent blood transfusions, chelation therapy to remove
excess iron from the blood, and hematopoietic stem cell transplantation (HSCT).
<img src="https://cdn.it.bgi.com/source/20230508_2023 International Thalassaemia Day_V3.2_02.jpg" style="max-width:100%;" contenteditable="false" width="100%"/>In
line with the theme of this year's International Thalassemia Day – "Be
Aware. Share. Care", BGI Genomics will co-host an event with the Shenzhen Municipal Health
Commission for thalassemia patients and their family members on May 6, 2023, in
Shenzhen, China, providing tips on thalassemia control and leading an HSCT donation
drive.&nbsp;This event will be followed by a seminar and another HSCT donation drive
for children with thalassemia in Chenzhou, Hunan province, China,&nbsp;on May 8, 2023 – International Thalassemia Day – where BGI Genomics will participate.&nbsp;&nbsp;"BGI
Genomics is a world leader in genomics research and has been dedicated to the
prevention and treatment of thalassemia for many years," commented Shiping
Chen, BGI Genomics Senior Product Manager. "We are working towards a vision that in a
not-too-distant future there will be a world without this disease."<h4>Contributing to thalassemia control worldwide</h4>The
company seeks to reach beyond China to countries along the 'Belt and Road
Initiative' to achieve comprehensive thalassemia control jointly, such as
Azerbaijan, one of the countries with the highest prevalence rate of
thalassemia worldwide. On May 3, 2023, the BGI Genomics Satellite Symposium was
held at the AZLTK &amp; LAB EXPO 2023, where experts discussed the application
of next-generation sequencing to prevent congenital disabilities, including
thalassemia.<img src="https://cdn.it.bgi.com/source/20230505-1a.jpg" style="max-width:100%;" contenteditable="false" width="100%"/><v:shapetype>
 <v:stroke>
 <v:formulas>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 <v:f>
 </v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:formulas>
 <v:path>
 <o:lock>
</o:lock></v:path></v:stroke></v:shapetype><v:shape>
 <v:imagedata>
</v:imagedata></v:shape>AZLTK &amp; LAB EXPO 2023In
September 2022, the Azerbaijan Thalassemia Center and BGI Genomics sealed a
<a target="_blank" href="https://www.bgi.com/global/news/bgi-and-atc-double-efforts-to-reinforce-thalassemia-prevention-in-azerbaijan">Collaboration Agreement</a>. The partnership aims to improve thalassemia screening
in Azerbaijan through genetic technology.<v:shape>
 <v:imagedata>
</v:imagedata></v:shape><img src="https://cdn.it.bgi.com/source/20230504-1.jpg" style="max-width:100%;" contenteditable="false"/>Azerbaijan Thalassemia Center and BGI Genomics signing ceremony
to seal a collaboration agreement<a target="_blank" href="https://www.bgi.com/global/news/bgi%E2%80%99s-thalassemia-gene-detection-kit-receives-ce-ivdd-certification">BGI'sThalassemia Gene Detection Kit</a> (Combinatorial Probe-Anchor Synthesis Sequencing
Method) obtained CE-IVDD approval in Europe and gained certifications in
Thailand and Saudi Arabia.This
detection kit uses the combinatorial probe-anchor synthesis sequencing method,
a next-generation sequencing (NGS) technology, to detect α-thalassemia and β
thalassemia mutations.&nbsp;Peripheral
blood samples will be used for genetic screening of the general population for
α and β thalassemia mutations and diagnosis of patients and suspected patients
with these mutations and abnormal hemoglobinopathy.It
has been estimated that 5-7 percent of the world's population carries a mutated
gene affecting the production or function of the hemoglobin molecule. In
high-prevalence regions of the world, hemoglobin disorders, such as
thalassemia, constitute a serious medical and public health problem. These
regions include the Mediterranean, the Middle Eastern and North African (MENA)
region, Central Asia, the Indian subcontinent, and Southeast Asia. <h4>About BGI Genomics&nbsp;</h4>





















































<a href="https://www.bgi.com/global" target="_blank">BGI Genomics</a>, headquartered in Shenzhen,
China, is the world's leading integrated solutions provider of precision
medicine. The company has pioneered thalassemia genetic testing services based
on next-generation sequencing (NGS) technology since 2013. In July 2017, as a
subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the
Shenzhen Stock Exchange.

BGI Genomics Promotes Thalassemia Awareness Worldwide – International Thalassemia Day

A Memorandum of Understanding (MoU) was signed on April 28, 2023,
between the Serbian Ministry of Health and BGI Genomics to strengthen existing
collaboration and exchange. <img src="https://cdn.it.bgi.com/source/20230504-2b.png" style="max-width:100%;" contenteditable="false"/>Signing of MoU between the Serbian Ministry of Health and BGI Genomics Under the MoU, both parties will enter a strategic partnership to promote genomics
testing in the clinical field, leverage resources and knowledge to further enhance
public health, and boost innovation. One of the projects to kick start the
partnership is a joint promotion program for colorectal cancer
prevention and early detection, using BGI Genomics' novel multi-target fecal <a href="https://colotectglobal.com/">DNA-based technology</a>.On April 25, 2023, Dr. Ye Yin, CEO &amp;
Executive Director of BGI Group, Dr. Ning Li, Vice President of BGI Genomics,
Ruiqi Xu, General Manager of BGI Genomics Europe Region, and Xiwen Jiang, Vice
General Manager of BGI Genomics Europe Region, met Prof. Danica Grujicic,
Minister of Health of Serbia.They exchanged views on optimizing collaboration in public health,
disease diagnosis, monitoring, and prevention. Both parties focused on cancer
prevention, early detection, and screening to reduce the incidence rate and
increase the survival rate of patients in Serbia. It is worth noting that the
Institute of Public Health in Serbia <a href="https://www.skriningsrbija.rs/eng/colorectal-cancer-screening/">reports</a> that colorectal
cancer is the second most common malignancy in morbidity and mortality. Around
4,500 people are diagnosed yearly, and <a href="https://www.jstor.org/stable/48504620">over 75 percent</a> of these cases are
diagnosed late, with higher mortality. During the COVID-19 pandemic, BGI Genomics helped build two
"Huo-Yan" Laboratories in Serbia, significantly improving the
detection capacity of the SARS-CoV-2 virus to fight the pandemic and save lives.
This laboratory is a comprehensive solution for nucleic acid detection and can
deliver testing solutions in reproductive health and oncology.In December 2021, in partnership with the Institute of Molecular
Genetics and Genetic Engineering (IMGGE) at the University of Belgrade, BGI
Genomics helped design and set up the Center for Genome Sequencing and
Bioinformatics, the very first genome sequencing hub in Serbia. Training was
also provided for whole exome sequencing (WES) and whole genome sequencing
(WGS), among others, enabling further progress in the research and development
of biomedicine and biotechnology within the country, using state-of-the-art
tools in molecular biology and information technology.The Center's new facilities enabled it to apply for
European-scale projects, such as Horizon Europe Program. The first project to
receive funding was "Pharmacogenomics Hub in a Strengthened IMGGE -
PharmGenHUB" where 250 whole genomes were sequenced. With
Serbia's strategic location in the Balkans, there is also scope for further
cooperation with neighboring countries since the transportation costs
associated with genome sequencing and cancer screening tests will be relatively
lower.BGI
Genomics is committed to research and delivering reliable solutions for
precision medicine, making genomic clinical applications more accessible and
affordable. Through a robust and long-term collaboration with the Serbian
Ministry of Health, the company looks forward to enhancing healthcare in Serbia
and beyond.Additional Reading:<a target="_blank" href="https://www.bgi.com/global/news/bgi-genomics-2023-global-state-of-colorectal-cancer-awareness-report">BGI Genomics 2023 Global State of Colorectal Cancer Awareness Report</a><a href="https://www.bgi.com/global/news/dna-methylation-tests-facilitate-earlier-colorectal-cancer-treatment-bgi-perspectives">DNA methylation tests enable better colorectal cancer treatment - BGI Perspectives</a>&nbsp; About BGI Genomics













































<a href="https://www.bgi.com/global">BGI
Genomics</a>, headquartered in Shenzhen, China, is the
world's leading integrated solutions provider of precision medicine. Our
services cover over 100 countries and regions, involving more than 2,300
medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics
(300676.SZ) was officially listed on the Shenzhen Stock Exchange.

Serbia Partners BGI Genomics to Enhance Healthcare through Novel DNA-based Testing Technology 

<img src="https://cdn.it.bgi.com/source/hugosigning.jpg" style="max-width:100%;" contenteditable="false"/>The Precision Oncology Center of Universidad Mayor, a leading Chilean university, obtained two cutting-edge sequencers and other equipment due to collaboration with BGI Genomics, allowing for more detailed genetic testing at half the cost and time of existing technologies."Knowing in detail the altered genes of a cancer patient's
tumor can mean a big difference for the success of the treatment since&nbsp;it makes it possible to
define which drug will be best to fight the disease,"&nbsp;says
Dr. Marcelo Garrido, director at the Precision Oncology Center (COP) of the
Universidad Mayor.With this goal,&nbsp;the Center, in partnership with BGI Genomics, recently
acquired two state-of-the-art sequencers&nbsp;that will allow oncologists throughout the
country to access unique technology in Chile to improve the treatment of their
patients."These
sequences will allow us to find out in Chile which altered genes patients have.&nbsp;Before, we had to send these samples abroad&nbsp;to other countries. This included very
high cost and delays in time to obtain a diagnosis," adds the specialist.The signing ceremony of the
agreement with BGI Genomics was held on April 18. It was attended by&nbsp;the Vice Chancellor of Research Nicole
Trefault and the general manager for Latin America, BGI Genomics, Liang Wu.Dr. Patricio Manque,&nbsp;Scientific Director of the Center,&nbsp;highlights that this is a
new step in consolidating the capacities of the U. Mayor in the area of
genomics.&nbsp;"The Precision Oncology Center puts medicine at the service of the people&nbsp;in an unprecedented effort to move towards
democratizing access to frontier medical treatments in the area of cancer, the
leading cause of death in our country.&nbsp;We now can rely on the most important sequencing laboratory in Chile&nbsp;with
equipment that allows analysis to be carried out in greater depth, in less time
and at a lower cost."<h2></h2><h2>Cutting edge technology </h2>The Center's new sequencers
purpose is to make thousands of copies of tumors' DNA to decode altered
genes. Such tools are based on precision oncology.Dr. Benjamin Garcia Bloj, clinical director of the Center, adds that&nbsp;"precision oncology involves the ability to
study patient's genetics to personalize cancer management&nbsp;and opt for better survival and less toxicity
compared to traditional approaches."The
doctor specifies that, although the sequencers are essential because they allow
to read with high precision tumor mutations, it is also important to have a
specialized team behind, able to interpret tests results.For this reason, the
Center has a Molecular Oncology Committee
involving a multidisciplinary team, both clinical and scientific, to&nbsp;analyze complex cases of cancer tumor profiles.&nbsp;<h2>"Many times we realize that genetically a different diagnosis has to be made and therefore the treatments change," says Dr. Garcia Bloj, who adds that "for complex cases, we determine the best line of treatment that the patient can currently receive in the country."</h2>Since its establishment in
2022,&nbsp;the Center has carried out over 850 clinical services and fifty clinical studies of cancer patients, implementing
personalized therapies based on the clinical tools of precision oncology.The Center has
previously established with pharmaceutical laboratories, clinics, hospitals,
primary health care services and patient associations to transfer their
technology and knowledge in cancer genomics.

















































Source: <a href="https://www.diariomayor.cl/ciencia-um/alianzas-centro-oncologia-precision-2023.html">Diario
Mayor</a>

News

Empowering Precision Medicine in Argentina, Brazil and Chile - BGI Updates

A Mother's Day Message from Uruguay and the U.S: Happy Parents Make for Happy Children

BGI Genomics Promotes Thalassemia Awareness Worldwide – International Thalassemia Day

Serbia Partners BGI Genomics to Enhance Healthcare through Novel DNA-based Testing Technology

Universidad Mayor Partners BGI Genomics to Form the Biggest Cancer Genomics Laboratory in Chile